Cascade Genetic Screening in Hereditary Transthyretin Amyloidosis: Unlocking Earlier Diagnosis and Improved Outcomes
Disease-Modifying Therapycascade genetic screeninggenetic counselinghereditary transthyretin amyloidosisearly diagnosis
Highlight
– Cascade genetic screening in ATTRv families identifies asymptomatic carriers who may develop disease earlier than predicted.
– Early diagnosis through screening correlates with improved survival compared to index cases.
– Disease-modifying therapies independently reduce mortality in ATTRv patients.
– Variant-specific follow-up protocols are critical due to variable penetrance and age of onset.
Study Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.